In all, 3,000 participants in the experiment, including 700 people with chronic pain problems, will receive drugs combining THC and CBD.
-1603097672.jpg "The first clinical trials on therapeutic cannabis will begin in 2021")
- The first trials on therapeutic cannabis will begin in France at the beginning of 2021.
- In all, 3,000 patients will be affected, including 700 suffering from chronic pain. These pains affect 5% of the population in France.
- The drugs will have a different ratio of THC and CBD depending on the patient, so that they can support the treatment as well as possible.
Almost a year after the authorization by the National Assembly of the first experiments on cannabis for therapeutic use in France, things are finally accelerating. A decree, signed on October 9, 2020 by the Minister of Health, finally opens the way to experimentation on French soil with medical cannabis. The first tests should normally take place in the first quarter of 2021.
For the moment, the National Agency for the Safety of Medicines (ANSM) is looking for companies that would be able to supply and import the desired therapeutic cannabis. For now, it seems that the majority of suppliers are Canadian.
A first assessment at six months
Cannabis medicines will be available in several forms, including capsules, to be taken sublingually (dissolve under the tongue) as well as in the form of vaporized dried flowers for acute pain attacks.
The first experiment will involve 3,000 people in France and overseas, 700 of whom are being treated for pain problems that cannot be solved with conventional treatments. These people, sorted and on the waiting list, suffer from chronic neuropathic pain, with lesions of the central and peripheral nervous system. They will be followed by one of the 49 health centers present on the metropolitan territory for six months in order to establish initial conclusions. In addition to this experiment, patients will keep their usual treatment.
The treatments will be through several specific CBD / THC ratios to optimize tolerance for patients. CBD (cannabidiol) serves to improve tolerance to the product while THC (tetrahydrocannabinol) is the active substance responsible for reducing pain.
If these trials are conclusive, they could be useful to a large number of people since the researchers estimate that neuropathic pain affects 5% of the population in France.
.
-1603097672.jpg&description=The+first+clinical+trials+on+therapeutic+cannabis+will+begin+in+2021){kind=link}